Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber.
10.08.2022 - Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development .